ArticleScience progress
A comparison between single and fractionated doses of albumin-bound paclitaxel in the treatment of advanced esophageal cancer: A multicenter case-control study.
Article in Science progress. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development and Validation of an Interpretable ML Model for Survival Prediction in Unresectable ESCC with Immunochemotherapy.Cancer management and research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAt present, albumin-bound paclitaxel combined with platinum is the standard first-line treatment option for advanced esophageal cancer (EC). However, following a hospitalization surge, clinicians may prefer to use albumin-bound paclitaxel as a single dose. The present study aimed to investigate the survival of patients with advanced EC when treated with single or fractionated doses of albumin-bound paclitaxel.
methodsWe collected survival data of patients with advanced first-line EC who had used albumin-bound paclitaxel with or without other treatment regimens from January 2018 to September 2023 at the Harbin Medical University Cancer Hospital and the Shanxi Province Cancer Hospital. The patients were divided into two groups according to the frequency and dose of albumin-bound paclitaxel administration, namely the abraxane fractional administration group (A group, 27 patients) and the abraxane single administration group (B group, 182 patients).
resultsThe median progression-free survival (PFS) was 9.0 months in both groups (
conclusionAlbumin-bound paclitaxel treatments showed no statistically significant differences in the PFS or OS. They were considered safe, whether administered as a single dose or in fractionated doses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.